🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Doxorubicin

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 63 trials in our China, USA, UK, Ireland and India registers that name Doxorubicin as an intervention. Synced 24 Sep 2026
63Trials tracked
29Recruiting now
40Lead sponsors
5Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov registry records · Last verified · Editorial standards

Doxorubicin is named as a drug or biological intervention in 63 clinical trials in our China, USA, UK, Ireland and India trial registers, 29 of which are recruiting. Lead sponsors include Merck Sharp & Dohme LLC (6), AstraZeneca (4) and Celgene (4). Registered phases: Phase 3, Phase 2, Phase 1/2, Phase 1, Phase 2/3, Phase 4 and Not applicable. Conditions studied include Breast Cancer; Endometrial Cancer; Diffuse Large B-Cell Lymphoma.

01

Clinical trials of Doxorubicin

63 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT06831370 A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India (ClinicalTrials.gov ↗)
Hodgkin Lymphoma
 Phase 4 Recruiting Takeda India
NCT01704716 High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) (ClinicalTrials.gov ↗)
Neuroblastoma
 Phase 3 Recruiting St. Anna Kinderkrebsforschung Ireland
NCT04043494 International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma (ClinicalTrials.gov ↗)
Lymphoblastic Lymphoma, Childhood
 Phase 3 Recruiting University Hospital Muenster Ireland, China
NCT04638790 First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)
Hodgkin Lymphoma, Adult
 Phase 3 Recruiting State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia India
NCT04685616 Brentuximab Vedotin in Early Stage Hodgkin Lymphoma (ClinicalTrials.gov ↗)
Hodgkin Lymphoma
 Phase 3 Recruiting University College, London Ireland
NCT06091254 A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Follicular Lymphoma (FL)
 Phase 3 Recruiting Regeneron Pharmaceuticals UK, USA
NCT06091865 A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma (ClinicalTrials.gov ↗)
Diffuse Large B-cell Lymphoma (DLBCL)
 Phase 3 Recruiting Regeneron Pharmaceuticals Ireland, UK, USA
NCT06340568 A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Endometrial Cancer
 Phase 3 Recruiting BioNTech SE UK, USA, China
NCT06394492 SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer (ClinicalTrials.gov ↗)
Ovarian Cancer
 Phase 3 Recruiting Suzhou Suncadia Biopharmaceuticals Co., Ltd. China
NCT06584032 Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer (ClinicalTrials.gov ↗)
Advanced Endometrial Cancer
 Phase 3 Recruiting Hutchmed China
NCT06717347 A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) (ClinicalTrials.gov ↗)
Diffuse Large B-Cell Lymphoma
 Phase 3 Recruiting Merck Sharp & Dohme LLC USA, China
NCT06855069 HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer (ClinicalTrials.gov ↗)
Ovarian Cancer
 Phase 3 Recruiting Hansoh BioMedical R&D Company China
NCT06911502 A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) (ClinicalTrials.gov ↗)
Follicular Lymphoma
 Phase 3 Recruiting Celgene UK, USA, India, China
NCT06966700 A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (ClinicalTrials.gov ↗)
Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
 Phase 3 Recruiting Merck Sharp & Dohme LLC UK, USA, India, China
NCT07044336 Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) (ClinicalTrials.gov ↗)
Endometrial Cancer, Malignant Solid Tumour
 Phase 3 Recruiting AstraZeneca UK, USA, China
NCT07441460 A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer (ClinicalTrials.gov ↗)
Resectable HER2-positive Breast Cancer
 Phase 3 Recruiting Shanghai JMT-Bio Inc. China
NCT06563245 Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment (ClinicalTrials.gov ↗)
Classical Hodgkin Lymphoma, Child, Adolescent
 Phase 2/3 Recruiting Children's Cancer Group, China China
NCT06277154 MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma (ClinicalTrials.gov ↗)
Leiomyosarcoma, Liposarcoma, Synovial Sarcoma
 Phase 2 Recruiting HRYZ Biotech Co. China
NCT06704555 Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma (ClinicalTrials.gov ↗)
Follicular Lymphoma
 Phase 2 Recruiting Tianjin Medical University Cancer Institute and Hospital China
NCT06803693 Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL (ClinicalTrials.gov ↗)
Diffuse Large B-Cell Lymphoma
 Phase 2 Recruiting Ruijin Hospital China
NCT06890884 A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) (ClinicalTrials.gov ↗)
Lymphoma, Large B-Cell, Diffuse
 Phase 2 Recruiting Merck Sharp & Dohme LLC Ireland, UK, USA
NCT04432714 Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement (ClinicalTrials.gov ↗)
DLBCL, Untreated, MYC Gene Rearrangement
 Phase 1/2 Recruiting The First Affiliated Hospital with Nanjing Medical University China
NCT04625907 FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma (ClinicalTrials.gov ↗)
Rhabdomyosarcoma
 Phase 1/2 Recruiting University of Birmingham Ireland
NCT05824975 A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) (ClinicalTrials.gov ↗)
Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)
 Phase 1/2 Recruiting GI Innovation, Inc. USA
NCT05981014 Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer (ClinicalTrials.gov ↗)
Breast Neoplasms
 Phase 1/2 Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University China
NCT06564038 A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma
 Phase 1/2 Recruiting AstraZeneca UK, USA, China
NCT07124936 A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma (ClinicalTrials.gov ↗)
Diffuse Large B Cell Lymphoma (DLBCL)
 Phase 1/2 Recruiting Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. China
NCT05785754 DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors (ClinicalTrials.gov ↗)
Advanced or Metastatic Solid Tumors
 Phase 1 Recruiting DynamiCure Biotechnology USA
NCT06121570 Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer (ClinicalTrials.gov ↗)
Breast Neoplasms
 Phase 1 Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University China
NCT07719855 A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma (ClinicalTrials.gov ↗)
Follicular Lymphoma ( FL)
 Phase 3 Not yet open Ruijin Hospital China
NCT07712588 Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) (ClinicalTrials.gov ↗)
Diffuse Large B-Cell Lymphoma (DLBCL)
 Phase 2/3 Not yet open Dizal Pharmaceuticals China
NCT06713057 Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer (ClinicalTrials.gov ↗)
Locally Advanced Thyroid Gland Carcinoma, Thyroid Cancer
 Phase 2 Not yet open West China Hospital China
NCT07231250 Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma (ClinicalTrials.gov ↗)
DLBCL - Diffuse Large B Cell Lymphoma, Chemo-free Therapy, Bispecific Antibody
 Phase 2 Not yet open Li Zhiming China
NCT07594899 AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL (ClinicalTrials.gov ↗)
Large B-Cell Lymphoma (LBCL)
 Phase 2 Not yet open Ruijin Hospital China
NCT07638787 Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL (ClinicalTrials.gov ↗)
Large B-cell Lymphoma
 Phase 1/2 Not yet open Ruijin Hospital China
NCT05287308 Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study (ClinicalTrials.gov ↗)
Breast Cancer
 Not applicable Not yet open Chinese Academy of Medical Sciences China
NCT06468943 Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL (ClinicalTrials.gov ↗)
Effects of Chemotherapy, Safety Issues
 Phase 2 By invitation The First Affiliated Hospital of Soochow University China
NCT03017326 Paediatric Hepatic International Tumour Trial (ClinicalTrials.gov ↗)
Hepatoblastoma, Carcinoma, Hepatocellular
 Phase 3 Active, closed University of Birmingham Ireland
NCT03725059 Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
Breast Cancer
 Phase 3 Active, closed Merck Sharp & Dohme LLC Ireland, UK, USA, China
NCT04529772 A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) (ClinicalTrials.gov ↗)
Diffuse Large B-Cell Lymphoma
 Phase 3 Active, closed Acerta Pharma BV USA, India, China
NCT04824092 Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (ClinicalTrials.gov ↗)
Diffuse Large B-cell Lymphoma
 Phase 3 Active, closed Incyte Corporation Ireland, UK, USA
NCT05113251 Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer (ClinicalTrials.gov ↗)
Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
 Phase 3 Active, closed AstraZeneca USA, India, China
NCT05578976 A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (ClinicalTrials.gov ↗)
Diffuse Large B-Cell Lymphoma
 Phase 3 Active, closed Genmab UK, USA, China
NCT05605899 Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (ClinicalTrials.gov ↗)
High-risk Large B-cell Lymphoma (LBCL)
 Phase 3 Active, closed Kite, A Gilead Company UK, USA
NCT06047080 An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma (ClinicalTrials.gov ↗)
Large B-Cell Lymphoma
 Phase 3 Active, closed Hoffmann-La Roche UK, USA, China
NCT06088290 Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) (ClinicalTrials.gov ↗)
Leiomyosarcoma
 Phase 3 Active, closed PharmaMar UK, USA
NCT06097364 A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma (ClinicalTrials.gov ↗)
Follicular Lymphoma (FL)
 Phase 3 Active, closed Regeneron Pharmaceuticals UK, USA
NCT06112379 A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (ClinicalTrials.gov ↗)
Breast Cancer
 Phase 3 Active, closed AstraZeneca UK, USA, India, China
NCT06132958 Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) (ClinicalTrials.gov ↗)
Endometrial Cancer
 Phase 3 Active, closed Merck Sharp & Dohme LLC Ireland, UK, USA, China
NCT06191744 Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (ClinicalTrials.gov ↗)
Follicular Lymphoma (FL)
 Phase 3 Active, closed Genmab UK, USA, China
NCT06356129 Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (ClinicalTrials.gov ↗)
Large B-cell Lymphoma
 Phase 3 Active, closed Celgene USA, India, China
NCT06486441 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) (ClinicalTrials.gov ↗)
Endometrial Cancer
 Phase 3 Active, closed Gilead Sciences UK, USA, China
NCT02641847 TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature (ClinicalTrials.gov ↗)
Triple Negative Breast Cancer, Breast Cancer
 Phase 2/3 Active, closed Fudan University China
NCT03407144 Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) (ClinicalTrials.gov ↗)
Hodgkin Lymphoma
 Phase 2 Active, closed Merck Sharp & Dohme LLC UK, USA
NCT03678883 9-ING-41 in Patients With Advanced Cancers (ClinicalTrials.gov ↗)
Cancer, Pancreatic Cancer, Sarcoma
 Phase 2 Active, closed Actuate Therapeutics Inc. USA
NCT04980222 A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma (ClinicalTrials.gov ↗)
Lymphoma
 Phase 2 Active, closed Hoffmann-La Roche USA
NCT05673785 A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL) (ClinicalTrials.gov ↗)
Lymphoma
 Phase 2 Active, closed Takeda China
NCT06425302 A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma (ClinicalTrials.gov ↗)
Lymphoma, Follicular
 Phase 2 Active, closed Celgene UK, USA
NCT02979522 A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma (ClinicalTrials.gov ↗)
Hodgkin Disease
 Phase 1/2 Active, closed Takeda USA
NCT04008797 A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor (ClinicalTrials.gov ↗)
Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular
 Phase 1/2 Active, closed Eisai Inc. USA, China
NCT05201248 A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma (ClinicalTrials.gov ↗)
B-Cell Non-Hodgkin Lymphoma
 Phase 1/2 Active, closed Genmab China
NCT05630209 Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)
Brain Tumor
 Phase 1/2 Active, closed InSightec USA
NCT04884035 Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma (ClinicalTrials.gov ↗)
Lymphoma, B-Cell
 Phase 1 Active, closed Celgene USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

70 conditions
Condition (as registered)Trials
Breast Cancer5
Endometrial Cancer4
Diffuse Large B-Cell Lymphoma4
Breast Neoplasms4
Hodgkin Lymphoma3
Follicular Lymphoma (FL)3
Large B-cell Lymphoma3
Carcinoma, Hepatocellular2
Follicular Lymphoma2
Leiomyosarcoma2
Lymphoma2
Ovarian Cancer2
Neuroblastoma1
Hepatoblastoma1
Rhabdomyosarcoma1
Diffuse Large B-cell Lymphoma (DLBCL)1
Lymphoblastic Lymphoma, Childhood1
Diffuse Large B-cell Lymphoma1
Lymphoma, Large B-Cell, Diffuse1
Chronic Lymphocytic Leukaemia1
Small Lymphocytic Lymphoma1
Mantle-cell Lymphoma1
Triple Negative Breast Neoplasms1
HR Low-Positive/HER2-Negative Breast Neoplasms1
High-risk Large B-cell Lymphoma (LBCL)1
Lymphoma, Follicular1
Large B-Cell Lymphoma1
Malignant Solid Tumour1
Brain Tumor1
Advanced Solid Tumor1
Metastatic Solid Tumor1
Soft Tissue Sarcoma (STS)1
Platinum-resistant Ovarian Cancer (PROC)1
Lymphoma, B-Cell1
Hodgkin Disease1
Advanced or Metastatic Solid Tumors1
Endometrial Neoplasms1
Neoplasms1
Liver Neoplasms1
Cancer1

+ 30 more conditions in the trial records above.

03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Merck Sharp & Dohme LLC6
AstraZeneca4
Celgene4
Ruijin Hospital4
Regeneron Pharmaceuticals3
Genmab3
Takeda3
University of Birmingham2
Hoffmann-La Roche2
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University2
St. Anna Kinderkrebsforschung1
University College, London1
University Hospital Muenster1
Incyte Corporation1
BioNTech SE1
Gilead Sciences1
PharmaMar1
Kite, A Gilead Company1
InSightec1
GI Innovation, Inc.1
DynamiCure Biotechnology1
Eisai Inc.1
Acerta Pharma BV1
Actuate Therapeutics Inc.1
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia1
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.1
Hutchmed1
Li Zhiming1
West China Hospital1
Shanghai JMT-Bio Inc.1
Tianjin Medical University Cancer Institute and Hospital1
Children's Cancer Group, China1
The First Affiliated Hospital with Nanjing Medical University1
Fudan University1
Chinese Academy of Medical Sciences1
Dizal Pharmaceuticals1
The First Affiliated Hospital of Soochow University1
Suzhou Suncadia Biopharmaceuticals Co., Ltd.1
HRYZ Biotech Co.1
Hansoh BioMedical R&D Company1
04

Trials by country register

RegisterDoxorubicin trials
Clinical trials in China41
Clinical trials in USA33
Clinical trials in UK21
Clinical trials in Ireland10
Clinical trials in India8

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Doxorubicin works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Doxorubicin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.